Recombinant human factor VIIa prevents hysterectomy in severe postpartum hemorrhage: Single center study

Journal of Perinatal Medicine

Volumn 40, Issue 1, 2012, Pages 43-49

  Huber, Alexander W ^a   Raio, Luigi ^a   Alberio, Lorenzo ^a   Ghezzi, Fabio ^b   Surbek, Daniel V ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b University Hospital   (Italy)

Author keywords

Hysterectomy; Postpartum hemorrhage; RhFVIIa

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; AMNION FLUID EMBOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; HYSTERECTOMY; OUTCOME ASSESSMENT; PLACENTA ACCRETA; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUERPERIUM; REPEATED DRUG DOSE; REPRODUCTIVE PROCEDURES; REVIEW; SINGLE DRUG DOSE; THROMBOEMBOLISM; TREATMENT RESPONSE; UTERINE ATONY; UTERUS INVERSION;

ADULT; FACTOR VIIA; FEMALE; FERTILITY PRESERVATION; HEMATOLOGIC TESTS; HUMANS; HYSTERECTOMY; POSTPARTUM HEMORRHAGE; PREGNANCY; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; YOUNG ADULT;

EID: 84856944439     PISSN: 03005577     EISSN: 16193997     Source Type: Journal    
DOI: 10.1515/JPM.2011.109     Document Type: Review

References (29)

1. Ahonen J, Jokela R, Korttila. An open non-randomized study of recombinant activated factor VII in major postpartum haemorrhage. Acta Anaesthesiol Scand. 2007;51:929-36. (Pubitemid 47062987)
2. Alanis M, Hurst BS, Marshburn PB, Matthews ML. Conservative management of placenta increta with selective arterial embo-lization preserves future fertility and results in a favorable outcome in subsequent pregnancies. Fertil Steril. 2006;86:1514. e3-7.
3. Alfirevic Z, Elbourne D, Pavord S, Bolte A, Van Geijn H, Mercier F, et al. Use of recombinant activated factor VII in primary post-partum hemorrhage: the Northern European registry 2000-2004. Obstet Gynecol. 2007;110:1270-8. (Pubitemid 351326069)
4. Boehlen F, Morales MA, Fontana P, Ricou B, Irion O, De Moerloose P. Prolonged treatment of massive postpartum haemorrhage with recombinant factor VIIa: case report and review of the literature. Br J Obstet Gynaecol. 2004;111:284-7. (Pubitemid 38299598)
5. Bouma LS, Bolte AC, van Geijn HP. Use of recombinant activated factor VII in massive postpartum haemorrhage. Eur J Obstet Gynecol Reprod Biol. 2008;137:172-7. (Pubitemid 351423462)
6. Bouwmeester FW, Bolte AC, van Geijn HP. Pharmacological and surgical therapy for primary postpartum hemorrhage. Current Pharmaceutical Design. 2005;11:759-73. (Pubitemid 40347979)
7. Breborowicz GH, Sobieszczyk S, Szymankiewicz M. Efficacy of recombinant activated factor VII (rFVIIa, Novoseven) in perinatal medicine. Arch Perin Med. 2002;8:21-7.
8. Dutton RP, McCunn M, Hyder M, D Àngelo M, O'Condor J, Hess JR, et al. Factor VIIa for correction of traumatic coagul-opathy. J Trauma. 2004;57:709-19. (Pubitemid 39431190)
9. Franchini M, Franchi M, Bergamini V, Montagnana M, Salvagno GL, Targher G, et al. Clin Obstet Gynecol. 2010;53:219-27.
10. Ghezzi F, Cromi A, Uccella S, Raio L, Bolis P, Surbek D. The Hayman technique: a simple method to treat postpartum haemorrhage. BJOG. 2007;114:362-5.
11. Hackethal A, Brueggmann D, Oehmke F, Tinneberg HR, Zygmunt MT, Muenstedt K. Uterine compression U-sutures in primary postpartum hemorrhage after Cesarean section: fertility preservation with a simple and effective technique. Hum Reprod. 2008;23:74-9. (Pubitemid 351767334)
12. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol. 2006;124:747-57. (Pubitemid 44066599)
13. Henrich W, Surbek D, Kainer F, Grottke O, Hopp H, Kiesewetter H, et al. Diagnosis and treatment of peripartum bleeding. J Perinat Med. 2008;36:467-78.
14. Jurlander B, Thim L, Klausen NL, Persson E, Kjalke M, Rexen P, et al. Recombinant activated factor VII (rFVIIa): characteriz ation,manufacturing,and clinical development. Semin Thromb Hemost. 2001;27:373-84.
15. Knight M. UKOSS. Peripartum hysterectomy in the UK: management and outcomes of the associated haemorrhage. BJOG. 2007;114:1380-7. (Pubitemid 47609949)
16. Lalinec-Michaud M, Engelsmann F. Anxiety, fears and depression related to hysterectomy. Can J Psychiatry. 1985;30:44-7. (Pubitemid 15146375)
17. Levi M, Peters M, Büller H. Efficacy and safety of recombi-nant factor VIIa for treatment of severe bleeding: A systematic review. Crit Care Med. 2005;33:883-90.
18. th report. London: RCOG, London, UK. 2004.
19. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127-37. (Pubitemid 351679599)
20. Mechsner S, Baessler K, Brunne B, Albrecht T, Hopp H, Dudenhausen JW. Using recombinant activated factor VII, B-Lynch compression, and reversible embolization of the uterine arteries for treatment of severe conservatively intractable postpartum hemorrhage: new method for management of massive hemorrhage in cases of placenta increta. Fertil Steril. 2008;90:2012.e1-5.
21. Meng ZH, Wolberg AS, Monroe DM III, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma. 2003;55:886-91. (Pubitemid 38004660)
22. Morris S, Ridley S, Munro V, Christensen MC. Cost effectiveness of recombinant activated factor VII for the control of bleeding in patients with severe blunt trauma injuries in the UK. Anesthesia. 2007;62:43-52. (Pubitemid 44869637)
23. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. J Am Med Assoc. 2006;295:293.
24. Pepas LP, Arif-Adib M, Kadir RA. Factor VIIa in puerpaeral hemorrhage with disseminated intravascular coagulation. Obstet Gynecol. 2006;108:757-61. (Pubitemid 44306417)
25. Phillips LE, McLintock C, Pollock W, Gatt S, Popham P, Jankelowitz G, et al. Australian and New Zealand Haemostasis Registry. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry. Anesth Analg. 2009;109:1908-15.
26. Segal S, Shemesh I Y, Blumental R, Yoffe B, Laufer N, Mankuta D, et al. The use of recombinant factor VII in severe postpartum hemorrhage. Acta Obstet Gynecol Scand. 2004;83:771-2. (Pubitemid 39062154)
27. Shander A, Goodnough LT, Ratko T, Matuszewski KA, Cohn S, Diringer M, et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (Novoseven) therapy. P&T. 2005;30:644-56.
28. Surbek DV, Fehr PM, Hösli I, Holzgreve W. Oral misoprostol for third stage of labor: a randomized placebo-controlled trial. Obstet Gynecol. 1999;94:255-8. (Pubitemid 29352872)
29. Welsh A, McLintock C, Gatt S, Somerset D, Popham P, Ogle R. Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage. Aust N Z J Obstet Gynaecol. 2008;48:12-6. (Pubitemid 351239149)